Feb 23, 2026 (MarketLine via COMTEX) --
CFO JA 1/4rgen Esser said sales could be hit by up to 1% in the opening three months of 2026.
Danone does not anticipate any tightening of regulations in the wake of the infant-formula recalls as the dairy giant pointed to a negligible impact on sales.
As the maker of Aptamil baby formula reported its full-year results on Friday (20 February), Danone said the aEURoecurrent financial impacts identified are not materialaEUR, although it added an aEURoeimpact assessment will be finalised once the recalls have been completedaEUR.
Nonetheless, as CEO Antoine de Saint-Affrique and CFO JA 1/4rgen Esser addressed analysts on a follow-up call, a financial impact was quantified for the first quarter of 2026.
aEURoeWe expect that supply disruption to have a one-off impact on our Q1 performance, and we estimate this one-off impact to be between 0.5-1% of net sales in the first quarter,aEUR Esser said.
Taking Danone's sales of ae6.84bn ($8.06bn) in the first quarter of 2025 as a yardstick, that would equate to around ae68.4m. DanoneaEUR(TM)s specialised nutrition division, which houses the infant-formula business, generated ae2.31bn in those three months.
NestlA(C) kicked off a recall around mid-December due to the presence of the Bacillus cereus bacteria in a brand of baby milk powders. Danone joined the recall in January - when its new fiscal year had already started - as notices expanded globally linked to the cereulide toxin, found by a number of manufacturers in an ingredient from a same supplier in China.
Providing its own annual results last week, NestlA(C) said it expected a one-off first-quarter impact of SFr200m ($257.6m) on sales from aEURoecustomer returns and stock shortagesaEUR but noted any aEURoeadditional impact is uncertainaEUR.
A loss of reputation and trust has been a key point raised by analysts for all companies involved in the recall and the potential impact on formula sales.
Pressed on FridayaEUR(TM)s Q&A session with analysts, de Saint-Affrique said: aEURoeWe donaEUR(TM)t see at this stage any major brand or brand equity impact on IMF [infant milk formula].
aEURoeThere is obviously a disturbance on the shelf. But from a pure brand and or category standpoint, we havenaEUR(TM)t seen anything major at this stage. Too early to say, we obviously look at it very, very carefully, but I wouldnaEUR(TM)t be definitive one way or the other.aEUR
CFO Esser added: aEURoeOur ambition is to win back trust and credibility because it is extremely important in that category. And itaEUR(TM)s obviously very early days. We need to monitor the situation very closely but the few data points that we have on market shares are rather reassuring.aEUR
Esser said Danone expects the recall aEURoesituation to normaliseaEUR during March in Europe and the Middle East where the company has pulled back products. China has been unaffected, he noted.
Meanwhile, de Saint-Affrique was dismissive of any regulatory tightening that might potentially emanate from the recalls although authorities in France and the wider EU have already lowered the permitted threshold for cereulide.
aEURoeWe donaEUR(TM)t see anything major but itaEUR(TM)s very, very early,aEUR he said. aEURoeIMF is a very, very regulated category. I think in our factories we have over 300 checkpoints when it comes to quality. There are rules in every country that are extremely, extremely strict. Do we expect a further strengthening of the regulation? Not in any major and significant way.aEUR
The CEO added: aEURoeWe are confident in the safety and quality of our products, which are supported by extensive scientific evidence and rigorous testing.
aEURoeThe entire focus of the organisation is fundamentally about two things: making sure that the products are back on shelf, and making sure that we do reassure our consumers and the healthcare professionals who are extremely active, both on the internet and in our care line.aEUR
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall
not be liable for errors or delays in the content, or for any actions
taken in reliance thereon
COMTEX_477152420/2227/2026-04-13T04:44:40
Copyright (C) 2026 Datamonitor. All rights reserved
